TY  - JOUR
A1  - Wild, Johannes
A1  - Schüler, Rebecca
A1  - Knopp, Tanja
A1  - Molitor, Michael
A1  - Kossmann, Sabine
A1  - Münzel, Thomas
A1  - Daiber, Andreas
A1  - Waisman, Ari
A1  - Wenzel, Philip
A1  - Karbach, Susanne Helena
T1  - Telmisartan lowers elevated blood pressure in psoriatic mice without attenuating vascular dysfunction and inflammation
T2  - International journal of molecular sciences
N2  - Background: Psoriasis is hallmarked by vascular dysfunction, arterial hypertension, and an increased risk for cardiovascular diseases. We have shown recently that skin-driven interleukin (IL)-17A expression promotes psoriasis-like disease in mice, and this is associated with vascular inflammation, vascular dysfunction, and hypertension. As an intensive risk-factor reduction is recommended for psoriasis patients, we aimed to elucidate the impact of the angiotensin II receptor type 1 (AT1) antagonist telmisartan in a mouse model of severe psoriasis-like skin disease.
Methods and Results: Elevated blood pressure measured by tail-cuff plethysmography in mice with keratinocyte-specific IL-17A overexpression (K14-IL-17Aind/+ mice) was significantly reduced in response to telmisartan. Importantly, vascular dysfunction, as assessed by isometric tension studies of isolated aortic rings, vascular inflammation measured by flow cytometry analysis of CD45+CD11b+ immune cells, as well as the increased peripheral oxidative stress levels assessed by L-012-enhanced chemiluminescence were not attenuated by telmisartan treatment of K14-IL-17Aind/+ mice, nor was the persisting skin inflammation.
Conclusion: We provide first evidence for an effective antihypertensive treatment in experimental psoriasis by AT1 blockade, but without any impact on vascular inflammation and dysfunction in our mouse model of severe psoriasis-like skin disease. This suggests that vascular function and inflammation in psoriasis might not be attenuated as long as skin inflammation persists.
KW  - psoriasis
KW  - vascular dysfunction and inflammation
KW  - Interleukin-17A
KW  - hypertension and anti-hypertensive treatment
KW  - telmisartan
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/52979
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-529795
SN  - 1422-0067
SN  - 1661-6596
N1  - This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
VL  - 20
IS  - 17, Art. 4261
SP  - 1
EP  - 10
PB  - Molecular Diversity Preservation International
CY  - Basel
ER  -